British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specialises in the treatment of rare gastrointestinal cancer GIST.
GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...
J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...
The global genital herpes treatment market is expected to grow at a CAGR of 5.2% from 2023 to 2033. Market valuation will ...
The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.
Dr Abdul Ghafur highlights how media narratives, public perception, and investor behaviour intersected during the HMPV scare, ...
The Brentford, England-based pharmaceutical and biotechnology firm said it will pay USD1.00 billion upfront for IDRx, a developer of precision therapeutics for the treatment of gastrointestinal ...
In a report released on January 9, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...
View the full release here: "I'm excited to welcome Alastair to Chemify to help us with building and scaling our ability to ...
The world’s largest study of proteins circulating the human body will begin in the UK this month, with the aim of pinpointing how diseases develop and paving the way for simple blood tests to detect ...
In a footnote of his opinion, Judge Joshua Roberts wrote, “A more cynical view of the circumstances is that plaintiffs’ ...
The FDA has mandated updated safety labeling for two respiratory syncytial virus vaccines, Pfizer's Abrysvo and GlaxoSmithKline's Arexvy, following the identification of an increased risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback